Gene:
PTGS2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)

PharmGKB contains no dosing guidelines for this gene. To report known dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this gene. To report a drug label with PGx, click here.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Position ? Drug ? Relevance ? Strength of
Evidence ?
rs20417

To see relevance please register or sign in.

3

Download a summary of all Clinical Annotations available.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

PharmGKB contains no genetic tests for this gene. To report genetic tests, click here.

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

Variant?
(build 132)
Alternate Names ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
rs20417 COX-2 G-765C, PTGS2:-765G>C, g.38138963C>G
C > G
Not Available
No VIP available No Clinical Annotations available VA
rs3218622
C > T
Missense
Arg228His
No VIP available No Clinical Annotations available VA
rs3218625
C > T
Missense
Gly587Arg
No VIP available No Clinical Annotations available VA
rs4648276
A > G
Not Available
No VIP available No Clinical Annotations available VA
rs5272
T > C
Missense
Glu488Gly
No VIP available No Clinical Annotations available VA
rs5273
A > G
Missense
Val511Ala
rs5275 COX-2 8473T>C, PTGS2 exon10+837T>C, PTGS2: 6498T>C, PTGS2:8473T>C, c.*427T>C, g.38131700A>G
A > G
Not Available
VIP No Clinical Annotations available No Variant Annotations available
rs689466 -1195G>A, COX-2 -1195G>A, g.38139393T>C
T > C
Not Available
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP build 132

Overview

Alternate Names:  OTTHUMP00000033524; PGH synthase 2; PHS II; cyclooxygenase 2b; cyclooxygenase-2; prostaglandin G/H synthase 2; prostaglandin G/H synthase and cyclooxygenase; prostaglandin H2 synthase 2; prostaglandin-endoperoxide synthase 2
Alternate Symbols:  COX-2; COX2; GRIPGHS; PGG/HS; PGHS-2; PHS-2; hCox-2
PharmGKB Accession Id: PA293

Details

Cytogenetic Location: chr1 : q31.1 - q31.1
GP mRNA Boundary: chr1 : 186640944 - 186649559
GP Gene Boundary: chr1 : 186637944 - 186659559
Strand: minus
Product Name: No data available
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Celecoxib Pathway, Pharmacodynamics
    Stylized cell depicting the mechanism of action of celecoxib and candidate genes interacting with celecoxib and involved in the regulation of cell cycle, apoptosis and angiogenesis by celecoxib.

External Pathways

Links to non-PharmGKB pathways.

  1. Calcineurin-regulated NFAT-dependent transcription in lymphocytes - (Pathway Interaction Database NCI-Nature Curated)
  2. Calcium signaling in the CD4+ TCR pathway - (Pathway Interaction Database NCI-Nature Curated)
  3. COX reactions - (Reactome via Pathway Interaction Database)
  4. Prostanoid hormones - (Reactome via Pathway Interaction Database)
  5. S1P1 pathway - (Pathway Interaction Database NCI-Nature Curated)
  6. Signaling mediated by p38-alpha and p38-beta - (Pathway Interaction Database NCI-Nature Curated)
No related genes are available

Curated Information ?

Curated Information ?

Publications related to PTGS2: 54

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenetics and genomics. 2012. Gong Li, et al. [Article:22336956@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic and genomic predictors of anti-TNF response. Pharmacogenomics. 2011. Prajapati Rita, et al. [Article:22044414@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interaction networks of lithium and valproate molecular targets reveal a striking enrichment of apoptosis functional clusters and neurotrophin signaling. The pharmacogenomics journal. 2011. Gupta A, et al. [Article:21383773@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Role of cyclooxygenase-2 and 5-lipoxygenase polymorphisms in Alzheimer's disease in a population from northern Italy: implication for pharmacogenomics. Journal of Alzheimer's disease : JAD. 2010. Listì Florinda, et al. [Article:20110601@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for PTGS2. Pharmacogenetics and genomics. 2010. Thorn Caroline F, et al. [Article:21063235@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic polymorphisms and the cardiovascular risk of non-steroidal anti-inflammatory drugs. The American journal of cardiology. 2010. St Germaine Christine G, et al. [Article:20538124@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Growth factor regulation of prostaglandin-endoperoxide synthase 2 (Ptgs2) expression in colonic mesenchymal stem cells. The Journal of biological chemistry. 2010. Walker Monica R, et al. [Article:20018844@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer. The pharmacogenomics journal. 2010. Ho-Pun-Cheung A, et al. [Article:20644561@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphic human prostaglandin H synthase-2 proteins and their interactions with cyclooxygenase substrates and inhibitors. The pharmacogenomics journal. 2010. Liu W, et al. [Article:20548327@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke. Atherosclerosis. 2009. Lemaitre Rozenn N, et al. [Article:19046748@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin. Cancer chemotherapy and pharmacology. 2009. Kim Jong Gwang, et al. [Article:19219602@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Role of inflammation gene polymorphisms on pain severity in lung cancer patients. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2009. Reyes-Gibby Cielito C, et al. [Article:19773451@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The genetics of antiplatelet drug resistance. Clinical genetics. 2009. Feher G, et al. [Article:19067731@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interaction of cyclooxygenase-2 variants and smoking in pancreatic cancer: a possible role of nucleophosmin. Gastroenterology. 2009. Zhao Dan, et al. [Article:19422084@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Variability in the response to cyclooxygenase inhibitors: toward the individualization of nonsteroidal anti-inflammatory drug therapy. Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 2009. Grosser Tilo. [Article:19602986@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics in cardiovascular antithrombotic therapy. Journal of the American College of Cardiology. 2009. Marín Francisco, et al. [Article:19744613@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genes that mediate breast cancer metastasis to the brain. Nature. 2009. Bos Paula D, et al. [Article:19421193@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Evolving novel anti-HER2 strategies. The lancet oncology. 2009. Jones Kellie L, et al. [Article:19959074@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-wide association scan identifies a prostaglandin-endoperoxide synthase 2 variant involved in risk of knee osteoarthritis. American journal of human genetics. 2008. Valdes Ana M, et al. [Article:18471798@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study. Atherosclerosis. 2008. Kohsaka Shun, et al. [Article:17350020@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circulation research. 2008. Arehart Eric, et al. [Article:18323528@PubMed]
Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. Clinical pharmacology and therapeutics. 2008. Lee C R, et al. [Article:17495879@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical use and pharmacological properties of selective COX-2 inhibitors. European journal of clinical pharmacology. 2008. Shi Shaojun, et al. [Article:17999057@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation. 2007. Maree Andrew O, et al. [Article:17452618@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The pharmacogenetics of antiplatelet drugs. Current opinion in investigational drugs (London, England : 2000). 2007. Marín Francisco, et al. [Article:17408116@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of EGFR and VEGF inhibition. Drug discovery today. 2007. Pander Jan, et al. [Article:18061885@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007. Ito Noriyuki, et al. [Article:17602083@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Pyrosequencing of polymorphisms in the COX-2 gene (PTGS2) with reported clinical relevance. Pharmacogenomics. 2007. Skarke Carsten, et al. [Article:18085997@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta activation. The Journal of experimental medicine. 2007. Ghosh Mallika, et al. [Article:17724132@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. The New England journal of medicine. 2007. Chan Andrew T, et al. [Article:17522398@PubMed]
Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs. Clinical pharmacology and therapeutics. 2006. Lee Yun-Sil, et al. [Article:16678543@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The cyclooxygenase 2 genetic variant -765G>C does not modulate the effects of celecoxib on prostaglandin E2 production. Clinical pharmacology and therapeutics. 2006. Skarke Carsten, et al. [Article:17178263@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology. 2006. Fries Susanne, et al. [Article:16401468@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenetics and genomics. 2006. Zhang Wu, et al. [Article:16788380@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hippocampal upregulation of the cyclooxygenase-2 gene following neonatal clomipramine treatment (a model of depression). The pharmacogenomics journal. 2006. Cassano P, et al. [Article:16568149@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2005. Ulrich Cornelia M, et al. [Article:15767339@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Colorectal adenoma risk is modified by the interplay between polymorphisms in arachidonic acid pathway genes and fish consumption. Carcinogenesis. 2005. Siezen Christine L E, et al. [Article:15550453@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology. 2005. Zhang Xuemei, et al. [Article:16083713@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. The New England journal of medicine. 2005. Bresalier Robert S, et al. [Article:15713943@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. The New England journal of medicine. 2005. Solomon Scott D, et al. [Article:15713944@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. The New England journal of medicine. 2005. Nussmeier Nancy A, et al. [Article:15713945@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochemical pharmacology. 2004. Chun Kyung-Soo, et al. [Article:15313405@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: the Singapore Chinese Health Study. British journal of cancer. 2004. Koh W-P, et al. [Article:15150618@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer research. 2004. Denkert Carsten, et al. [Article:14729623@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HMG-CoA reductase inhibitors induce COX-2 gene expression in murine macrophages: role of MAPK cascades and promoter elements for CREB and C/EBPbeta. Experimental cell research. 2004. Chen Jui-Ching, et al. [Article:15530865@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Relationship between COX-2 specific inhibitors and hypertension. Hypertension. 2004. Solomon Daniel H, et al. [Article:15226279@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA : the journal of the American Medical Association. 2004. Cipollone Francesco, et al. [Article:15138244@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
COX-2 inhibition and cancer: experimental findings and clinical correlates. The West Virginia medical journal. 2004. Roberts Elizabeth Gail, et al. [Article:15384741@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The RNA-binding protein HuR regulates the expression of cyclooxygenase-2. The Journal of biological chemistry. 2003. Sengupta Sibani, et al. [Article:12704185@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
COX-2-selective inhibitors in the treatment of arthritis. Cleveland Clinic journal of medicine. 2002. Schnitzer Thomas J, et al. [Article:12086290@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38. Molecular and cellular biology. 2001. Lasa M, et al. [Article:11154265@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Celecoxib, a COX-2--specific inhibitor: the clinical data. American journal of orthopedics (Belle Mead, N.J.). 1999. Fort J. [Article:10193998@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Repression of cyclooxygenase-2 and prostaglandin E2 release by dexamethasone occurs by transcriptional and post-transcriptional mechanisms involving loss of polyadenylated mRNA. The Journal of biological chemistry. 1998. Newton R, et al. [Article:9822711@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. The Journal of biological chemistry. 1996. Smith W L, et al. [Article:8969167@PubMed]

LinkOuts

Entrez Gene:
5743
OMIM:
600262
UCSC Genome Browser:
NM_000963
RefSeq RNA:
NM_000963
RefSeq Protein:
NP_000954
RefSeq DNA:
AC_000044
AC_000133
NC_000001
NT_004487
NW_001838533
NW_926128
UniProtKB:
PGH2_HUMAN (P35354)
Ensembl:
ENSG00000073756
GenAtlas:
PTGS2
GeneCard:
GC01M186640 (5743)
MutDB:
PTGS2
ALFRED:
LO047741X
HuGE:
PTGS2
Comparative Toxicogenomics Database:
5743
ModBase:
P35354
HumanCyc Gene:
HS01115
HGNC:
9605

Common Searches

PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (R24 GM61374).
©2001-2012 PharmGKB.